Bildnachweis: Nuclidium.
Nuclidium, a clinical-stage radiopharmaceutical company, has announced the successful closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension round, bringing the total Series B financing to CHF 105 million (approximately EUR 115 million). The financing round was led by existing investors Kurma Growth Opportunities Fund and Angelini Ventures, alongside EIB co-investment facility Aurea, Wellington Partners and Neva SGR (Intesa Sanpaolo Group). Additional participation came from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, NRW.Bank, as well as further existing investors.
The proceeds will be used to accelerate and broaden the clinical development of Nuclidium’s lead radiotheranostic programmes, NU101 for metastatic castration-resistant prostate cancer (mCRPC) and NU201 for metastatic breast cancer (mBC), advancing both assets into later-stage clinical trials. The company also intends to expand its global production and manufacturing network for diagnostic and therapeutic applications, while further progressing novel target development across its preclinical pipeline. “Emerging data from our Phase 1/2 diagnostics studies continue to generate strong momentum for NUCLIDIUM’S true radiotheranostics approach. We will build on our programs’ best-in-class potential by initiating Phase 1/2a therapeutic studies for NU-101 and NU-201 later this year, demonstrating our direct conversion strategy from diagnosis to treatment. The Series B extension and support from our world-class investors further validate our strategy to advance next-generation copper-based radiotheranostics and unlock the full potential of the theranostic modality,” said Leila Jaafar, PhD, CEO and Co-Founder of Nuclidium.
Rapidly expanding radiopharmaceuticals market
Investors highlighted the company’s differentiated positioning within the rapidly expanding radiopharmaceuticals market. “Radiopharmaceuticals are one of the most compelling growth opportunities in oncology today. Nuclidium has established clear differentiation with its copper-based radiotheranostic approach, demonstrating clinical superiority to competing radioligands and ease-of-use that supports seamless integration into hospital workflow. We are proud to support Nuclidium through this new phase of growth as it advances its pipeline toward additional clinical proof-of-concept data,” said Regina Hodits, PhD, Managing Director at Angelini Ventures, Daniel Parera, MD, Partner at Kurma Partners and Mario Costantini, CEO and General Manager at Neva SGR (Intesa Sanpaolo Group) for all participating investors.
